Atea Pharmaceuticals Inc has a consensus price target of $6.44 based on the ratings of 3 analysts. The high is $6.88 issued by Morgan Stanley on August 13, 2024. The low is $6 issued by SVB Leerink on January 27, 2023. The 3 most-recent analyst ratings were released by Morgan Stanley, JP Morgan, and SVB Leerink on August 13, 2024, March 16, 2023, and January 27, 2023, respectively. With an average price target of $6.96 between Morgan Stanley, JP Morgan, and SVB Leerink, there's an implied 78.46% upside for Atea Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Atea Pharmaceuticals (NASDAQ:AVIR) was reported by Morgan Stanley on August 13, 2024. The analyst firm set a price target for $6.88 expecting AVIR to rise to within 12 months (a possible 76.41% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Atea Pharmaceuticals (NASDAQ:AVIR) was provided by Morgan Stanley, and Atea Pharmaceuticals upgraded their equal-weight rating.
The last upgrade for Atea Pharmaceuticals Inc happened on August 13, 2024 when Morgan Stanley raised their price target to $6.88. Morgan Stanley previously had an underweight for Atea Pharmaceuticals Inc.
The last downgrade for Atea Pharmaceuticals Inc happened on August 10, 2023 when JP Morgan changed their price target from N/A to N/A for Atea Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on August 13, 2024 so you should expect the next rating to be made available sometime around August 13, 2025.
While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a upgraded with a price target of $2.00 to $6.88. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.90, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.